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The magnitude of the breast cancer problem implores researchers to aggressively investigate
prevention strategies. However, several barriers currently reduce the feasibility of breast cancer
prevention. These barriers include the inability to accurately predict future breast cancer
diagnosis at the individual level, the need for improved understanding of when to implement
interventions, uncertainty with respect to optimal duration of treatment, and negative side
effects associated with currently approved chemoprevention therapies. None-the-less, the unique
biology of the mammary gland, with its postnatal development and conditional terminal
differentiation, may permit the resolution of many of these barriers. Speciﬁcally, lifecycle-
speciﬁc windows of breast cancer risk have been identiﬁed that may be amenable to risk-
reducing strategies. Here, we argue for prevention research focused on two of these lifecycle
windows of risk: postpartum mammary gland involution and peri-menopause. We provide
evidence that these windows are highly amenable to targeted, limited duration treatments. Such
approaches could result in the prevention of postpartum and postmenopausal breast cancers,
correspondingly.
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The ﬁeld of cancer prevention was formalized in the 1970s and
coincided with the recognition that most cancers develop through
a multi-step process with long latency [1]. Establishing that
cancer progression spans from initiation to overt metastasis
energized the cancer research community to consider prevention
strategies. Based on current incidence rates, the appeal of
preventing cancer is self-evident. In the US, it is predicted that
almost 50% of men and 33% of women will be diagnosed with
cancer in their lifetime [2]. Breast cancer, which is the focus of
this review, is a signiﬁcant health problem worldwide. In 2010
there were an estimated 1.5 million cases of breast cancer
diagnosed, representing nearly a quarter of all cancer diagnoses
in women. Breast cancer is now the leading cause of cancer death
in economically developed countries, a statistic in stark contrast
to the low death rate from cervical cancer due to successful
prevention [3]. Despite medical advances in breast cancer detec-
tion and treatment, mortality remains a global problem and
further, access to care is limited in many countries. Thus, breast
cancer represents an optimal cancer to target for prevention
research, particularly if the outcome is generalizable and
inexpensive.Overview of breast cancer prevention success to date
Conceptually, there are multiple strategies for breast cancer
prevention. Primary prevention is focused on blocking tumor cell
initiation by minimizing carcinogen exposure or enhancing
detoxiﬁcation. Examples include avoiding the use of ionizing
radiation on developing breast tissue, limiting exogenous estro-
gen exposure, and supplementation with dietary agents such as
the cruciferous isothiocyanates, which activate the p450 carcino-
gen metabolism pathway [4]. The ability to prevent breast cancer
through targeted drug therapy, or chemoprevention, has also
been successful with the use of selective estrogen receptor
modulator (SERMs) [5,6]. Unfortunately, despite research success
with SERMs, signiﬁcant challenges remain [7]. Barriers to the
implementation of successful large-scale prevention efforts have
been identiﬁed from the ﬁrst generation breast cancer prevention
trials and subsequent follow up studies [7]. While a comprehen-
sive summary of these trials is beyond the scope of this short
review, we brieﬂy cover many of the salient points, in order to
help inform future trials.Breast cancer was the ﬁrst malignancy where targeted drug
treatment trials in the adjuvant setting demonstrated a concomi-
tant secondary prevention beneﬁt for subsequent contralateral
disease. An average 50% reduction in new primary breast cancers
was identiﬁed among women treated for 5 years with the SERM,
tamoxifen [5]. These data supported the ensuing landmark
NSABP-P1 randomized clinical trial for the primary prevention
of breast cancer, enrolling women over age 35 who had a higher
than 1.6% risk of developing breast cancer within the next 5 years
[5]. A similar degree of beneﬁt was observed, with a 49%
reduction in incidence of estrogen-positive breast cancer, result-
ing in tamoxifen′s approval as the ﬁrst chemopreventive agent in
1998 [5]. The second generation SERM, raloxifene, was approved
10 years later, and is approximately 75% as effective as tamoxifen
in preventing breast cancer with signiﬁcantly fewer side effects
[6]. More recently, the aromatase-inhibitor exemestane given to
high risk post-menopausal women for 5 years reduced annual
incidence of invasive breast cancer by 65% [8]. This study
conﬁrms efﬁcacy of aromatase-inhibition for prevention in post-
menopausal women who are at increased risk for breast
cancer [8].
Given the clinical success of anti-hormone based chemopreven-
tion, it is surprising that of the more than 2 million high-risk
women in the US alone, the number of women using tamoxifen
for prevention is declining, with reports of 120,000 in 2000 to
20,500 in 2010 [7]. Similarly, in 2010, 96,000 postmenopausal
women used raloxifene as primary chemoprevention, suggesting
it too is not embraced by the vast majority of high-risk women.
Data on acceptance of the aromatase inhibitor exemestane is not
yet available. So, why do high risk women choose not to take
SERMs to reduce risk for breast cancer? Reported barriers to
chemoprevention acceptance include lack of risk knowledge
among women, toxicity, and selected beneﬁt speciﬁc for estrogen
receptor (ER) positive tumors.
The toxicity proﬁle and therapeutic index of SERM therapy is a
clearly identiﬁed detractor to the drug's acceptance among
women [6,7]. When the potential beneﬁts of tamoxifen use by
high-risk postmenopausal women are examined, estimates indi-
cate that one case of breast cancer is prevented for every 35
women treated, and one breast cancer death prevented by
treating 102 women [9]. However, for each 1000 who select
tamoxifen as prevention, 3 are anticipated to develop endometrial
cancer and 2–3 will experience a signiﬁcant thromboembolic
event [5–7]. There are also a number of other complications from
SERM chemoprevention agents that limit the drug's acceptability,
including worsening of menopausal symptoms, sexual
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symptoms [5,6,8].
An additional limitation to women embracing breast cancer
chemoprevention strategies is that many women may not be
informed of their increased risk and thus do not know they are
candidates for preventive strategies. While several models are
currently utilized to predict a woman's breast cancer risk and
guide indication for chemoprevention, a comprehensive model
that incorporates all known risk factors does not exist. The Breast
Cancer Risk Assessment Tool (BCRAT), also known as the GAIL
model, is commonly used to deﬁne high-risk women by predict-
ing 5-year and lifetime breast cancer risks. To predict breast
cancer risk, the GAIL model uses current age, age at menarche, age
at ﬁrst birth, number of ﬁrst degree relatives with breast cancer,
number of previous breast biopsies, and any pre-malignant
histology results, with age being the most heavily weighted factor
[10]. Another model used clinically in the US is the International
Breast Cancer Intervention Study Model (IBIS or Tyler Cuzick
model). The IBIS model adds BRCA1/2 genetic status, age at
menopause, and hormone replacement therapy, which are all
potential risk factors not included in the GAIL model [10]. A recent
comparison of these two models for accuracy in predicting breast
cancer risk found that the IBIS model was in closer agreement to
the actual observed incidence in the study cohort, a result likely
due to the inclusion of the additional risk factors in the IBIS model
[10]. Importantly, neither model accounts for breast density [11],
age-related breast involution following menopause [12] or the
risk for breast cancer observed in young women during the
postpartum period [13]. Thus, the development of additional risk
prediction models that incorporate all known risk factors for
breast cancer is critical to more accurately identify women who
might beneﬁt from chemoprevention.
Finally, an additional limitation of endocrine based chemopre-
vention agents is their selection against only ER positive breast
cancers. Thus, SERM therapy is predicted to prevent only 38% of
breast cancers during the time of treatment and would, therefore,
be ineffective for the majority of women [14]. The need for
chemoprevention that would prevent the more aggressive Her-
2/neu positive and triple negative breast cancer subtypes
remains unmet.How best to improve upon the success of
chemoprevention for breast cancer?
The ideal chemoprevention agent would be highly effective at
eliminating breast cancer with few off-target effects, required for
a limited duration of time, and inexpensive. The SERMs meet each
of these ideals only partially, as discussed above. None-the-less,
tamoxifen is a success story for chemoprevention when compared
to other agents tested against lung and prostate cancer, and
important lessons learned from these studies need to guide
further prevention research. For example, data from epidemiolo-
gical and preclinical animal-model studies suggest that there are
key components of the diet that are cancer-protective. These data
led to a number of vitamin-based intervention trials, where,
unfortunately, the results were not as expected. For example,
not only did vitamin E fail to decrease risk of prostate cancer in
high-risk men [15], and vitamin E and beta carotene fail to reduce
lung cancer incidence in high-risk smokers [16], but theseinterventions actually increased cancer incidence. Cumulatively,
these and other studies bring to light several critical issues for the
chemoprevention ﬁeld. First, the evaluation of unique populations
to identify a single dietary component responsible for increased
cancer rates is likely a ﬂawed approach. Second, validation of
chemopreventive efﬁcacy in animal models does not necessarily
predict efﬁcacy in humans. Third, these studies did not address
the appropriate time in a person's life or the duration of treatment
that is required to reduce cancer risk. And ﬁnally, as demonstrated
by the success of tamoxifen, testing agents that have shown
clinical efﬁcacy in human therapies may result in more successful
chemoprevention.
Breast cancer prevention leads from observational studies
Observational studies have addressed the potential for use of non-
steroidal anti-inﬂammatory drugs (NSAIDs) as breast cancer
preventive agents, with mixed results. In prospective outcome
studies, use of the non-selective COX-2 inhibitors aspirin and
ibuprofen was associated with decreased recurrence and breast
cancer related death [17,18]. However, a relationship between
COX-2 and breast cancer risk is less evident, with studies
reporting either a moderate protective effect or no correlation
with use of COX-2 inhibitors [19–24]. A recent, large observational
study of 84,602 postmenopausal women investigated NSAIDs and
breast cancer risk by following unaffected women for 28 years. In
this study, use of aspirin, other NSAIDs, and acetaminophen did
not signiﬁcantly reduce risk for postmenopausal breast cancer,
either overall or by speciﬁc breast cancer subtype [25]. These
ﬁndings support previous results reported in the Cancer Preven-
tion Study II Nutrition cohort [23], but are in contrast to a recent
meta-analysis of studies published between 1950 and 2011, which
found a signiﬁcant reduction in risk with daily aspirin use
(OR¼0.81; 95% CI¼0.72–0.93) and any aspirin use (OR¼0.88;
95% CI¼0.82–0.95) [26]. Furthermore, in a case-control study, a
large reduction in adjusted overall risk for invasive breast cancer
(OR¼0.4, 95% CI¼ 0.3–0.6) was observed with NSAID use [27].
Collectively, these studies indicate a potential for NSAIDs in the
prevention of breast cancer and importantly indicate no increased
risk for breast cancer associated with NSAIDs. However, none of
these observational studies address the important questions of
which group of at-risk women is most likely to beneﬁt from
NSAID chemoprevention, when during a woman's life treatment
should be administered, or the optimal dose and duration of
treatment.
In addition to the NSAID observational studies, evidence is
increasing that COX-2 is causally involved in early stage breast
cancer and thus a viable target for prevention. Thea Tlsty and
colleagues have studied COX-2 expression in early malignant
human tissues and shown that ductal carcinoma in situ (DCIS)
lesions, along with normal breast epithelium adjacent to DCIS,
express high levels of COX-2. In their cohort, expression was
highest in the normal tissue adjacent to DCIS, implicating the
upregulation of COX-2 in the very earliest stages of transforma-
tion [28]. Furthermore, high COX-2 expression was observed in a
subpopulation of patient-derived ‘variant’ mammary epithelial
cells that also exhibit chromosomal and telomeric abnormalities
consistent with pre-malignancy [29]. Finally, in a case control
study of 1162 women with DCIS, an association between COX-2/
p16/Ki67 triple positivity in DCIS lesions and subsequent invasive
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COX-2 inhibition as an approach to block progression of pre-
malignant changes to overt breast cancer.Physiologic, lifecycle windows for targeted
chemoprevention
Based on experience gained to date, it is clear that several barriers
signiﬁcantly reduce both the feasibility of breast cancer preven-
tion and patient conﬁdence in these strategies. As described
above, barriers include the inability to accurately predict at the
individual level an impending or future breast cancer, the need to
understand when in a woman's life to implement the interven-
tion, uncertainties regarding optimal duration of treatment, and
negative side effects associated with current drugs. None-the-less,
the unique biology of the mammary gland will likely permit the
resolution of many of these barriers, making breast cancer
prevention a viable objective. Not only does the majority of
mammary gland development occur postnatally, but terminal
differentiation is conditional and developmentally plastic. While
these features may contribute to the high susceptibility of the
breast to transformation, these feature have also permitted the
identiﬁcation of lifecycle-speciﬁc windows of breast cancer risk
that may be amenable to therapeutic interventions [31].
The unique biology of the breast begins in utero with breast
ductal anlagen development (Fig. 1). After birth the ductal
architecture grows slowly, in synchrony with the growing, pre-
pubescent child. With puberty, development of ductal side-
branches and alveoli ensue, ﬁlling the mammary fat pad with a
mature ductal tree containing small alveoli that are poised to
respond to pregnancy hormones. Pregnancy drives alveolar pro-
liferation and differentiation, and at parturition, activation of
lactation occurs. Importantly, terminal differentiation of the gland
is achieved only with full term pregnancy and lactation. Post-
partum mammary gland involution, whereby the gland remodels
to a state morphologically and functionally similar to pre-preg-
nancy, occurs after parturition in the absence of lactation, or at
weaning. Throughout the reproductive years, the non-secretory,PubertyChildhood
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Fetal
Lac
Lifecycle Windows of Risk
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Collagen rich extracellular matrix
Radial alligened collagen
Protease
Monocytes
Lymphocytes
In utero
Pregnancy
Par
Nullip
Fig. 1 – Lifecycle windows of risk for breast cancer. Schematic pres
pregnancy, lactation, and involution cycle of the breast is offset to
(nulliparous). The four windows of cancer vulnerability are deﬁne
related involution. Data compiled in part from Refs. [12,13,32–35,4relatively quiescent gland can repeat the differentiation/involu-
tion cycle in response to pregnancy and lactation signals. Finally,
in the peri-menopausal window, with declining ovarian function,
the gland begins age-related involution and alveolar lobules
regress. With menopause, ovarian hormone stimulation is lost
and age-related involution goes to completion in most women
[12]. From a breast cancer perspective, the ‘lifecycle’ of the breast
can be divided into ﬁve windows of cancer vulnerability: in utero,
pubertal, pregnancy, postpartum involution, and age-related
involution [12,13,31–35]. Importantly, each of these identiﬁed
windows of risk is limited in duration and the at-risk populations
are identiﬁable. We propose that by combining these ‘lifecycle
windows’ of risk with known risk factor assessments, possibly in
conjunction with genetic analysis of breast cancer susceptibility
loci, several major barriers that currently limit breast cancer
prevention can be overcome. Speciﬁcally, this approach would
more accurately identify high risk cohorts, identify windows of
intervention, and limit treatment to the duration of the develop-
mental window being targeted. Further, the hallmark of these
‘lifecycle windows’ of risk is tissue remodeling driven by devel-
opmentally regulated programs that engage both the mammary
epithelium and the stroma [34,36–38]. Thus targets for preven-
tion can encompass both tissue compartments, greatly broad-
ening the number of potential agents to be considered.
Pivotal epidemiologic studies established that lifecycle events
predict breast cancer risk, including age at puberty, the number of
menstrual cycles across a lifetime, age at ﬁrst birth, multiparity,
and age at menopause [32,39]. Importantly, these studies led to
the idea that targeting certain time periods of a women's life is a
viable strategy for breast cancer prevention [34,35,38,40,41].
However, not all of the ‘windows’ of breast cancer risk are equally
suitable for translation to the clinic. While prevention strategies
aimed at the in utero or pubertal windows have the potential to
dramatically decrease cancer incidence, targeting these vulner-
able populations with chemoprevention drugs is justiﬁably con-
troversial. Speciﬁcally, the impact of systemic interventions
designed to alter the susceptibility of nascent breast tissue to
subsequent transforming events could have signiﬁcant, unfore-
seen consequences on the function of other developing organs.Peri-
menopause
Postpartum
Involutiontation
Post-
menopause
Age-Related 
Involution
ous
arous
entation of the lifecycle of breast development in women. The
distinguish parous from women who have never been pregnant
d by red text: fetal, puberty, postpartum involution, and age-
1,44].
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the undesirable cross-targeting of the developing fetus. However,
postpartum involution and peri-menopause/menopause windows
are unencumbered by these potential problems and prevention
strategies targeting these windows should be aggressively
investigated.Postpartum involution window of risk
Multiple, large population studies demonstrate a transient
increase in risk for breast cancer that occurs after each childbirth,
regardless of the woman's age [42–45]. Albrektsen et al. designate
the window of increased incidence within 10 years of a completed
pregnancy [44]. Data show that this postpartum risk is highest
and lasts longest in women who are older than age 30 at the time
of ﬁrst childbirth [44,45]. Furthermore, survival rates for cases
diagnosed within 5 years of giving birth are signiﬁcantly reduced,
making prevention of postpartum breast cancer a priority [13,46–
48].
To prevent the incidence of postpartum breast cancer, we must
ﬁrst understand how this unique life window promotes breast
cancer. While pregnancy hormones are obvious candidates, the
postpartum window also includes the unique process of mam-
mary gland involution, which contributes to breast cancer pro-
gression in rodent models [49]. During involution, the vast
majority of the milk secreting mammary epithelial cells undergo
apoptosis and tissue remodeling ensues, restoring the epithelial/
stromal ratio to a stromal-dominant, pre-pregnant-like state [50–
56]. Multiple studies by our group and others have shown in
rodents that the process of postpartum mammary gland involu-
tion utilizes wound healing programs to remodel the gland
[52,54,56]. These same wound-like programs are also associated
with tumorigenesis, implicating stromal remodeling of postpar-
tum involution as a driver of postpartum breast cancer progres-
sion [13]. For example, mammary gland involution is
characterized by immune cell inﬁltration, particularly alterna-
tively activated macrophages, elevation of COX-2 protein,
increased matrix metalloproteinase 1, 2, 3 and 9 activity, extra-
cellular matrix remodeling, and new matrix deposition including
ﬁbrillar collagen and the pro-tumorigenic extracellular matrix
protein, tenascin-C [37,49,52,57]. Further, the collagen architec-
ture in the involuting mammary gland resembles that which
promotes tumor cells in culture and predicts poor prognosis in
breast cancer patients [49,58]. In support of the postpartum
involution being tumor promotional, pre-clinical models show
that the involuting gland promotes the progression of non-
metastatic, DCIS like lesions to invasive tumors that have
increased collagen deposition and COX-2 expression [49,59].
The identiﬁcation of the mechanisms by which the postpartum
involuting breast may promote breast cancer has opened the
potential for speciﬁc chemoprevention strategies that target this
at-risk population. The increase in COX-2 expression during
involution provides support for targeting the COX-2 pathway
and proof of concept was shown using a preclinical model of
postpartum breast cancer. In this model, inhibition of COX-2, via
NSAID administration during the two week period of murine
postpartum involution, reduced mammary gland collagen deposi-
tion, decreased tumor COX-2 expression, and blocked tumor cell
growth and invasion [49]. Importantly the process of involutionappeared morphologically normal with NSAID treatment [57].
Collectively, the results from these studies indicate that NSAIDs
target both the stromal and epithelial components of the post-
partum involuting gland to reduce tumorigenicity and this occurs
without interfering with the requisite death of the secretory
epithelium. Moreover, these pre-clinical data suggest that post-
partum breast involution is a rational and promising life window
to target in women. Moving forward, it will be critical to
determine to what extent the pro-tumorigenic programs of
postpartum involution identiﬁed in rodents apply to the human
breast [60]. Also, thorough safety studies must be performed to
rule out any unforeseen negative side effects that NSAID treat-
ment may have when women are treated speciﬁcally in the
postpartum period [60].Peri-menopause/menopause window of risk
Age related involution that occurs with menopause has been
identiﬁed as marker of breast cancer risk; however the mechan-
ism remains unknown [38]. Menopause represents a time when
obesity, energy balance, circulating hormones, chemokines and
cytokines, and body fat distribution are in ﬂux, and is also the
critical time when the tumor-promoting effects of obesity emerge.
Obesity's impact on breast cancer prior to menopause is relatively
modest and in some cases has even been shown to be protective
[61]. After menopause, however, obesity increases the incidence,
progression, and eventual mortality from breast cancer by up to
40% compared to women at a healthy weight [62]. In further
support of the negative effects of excess body weight on breast
cancer, results of the Iowa Women's Health Study show that
intentional loss of at least 20 pounds was associated with a 19%
decrease in incidence of postmenopausal breast cancer [63].
Similarly the Nurses' Health Study found that women who gained
weight as adults had increased risk of breast cancer after
menopause, whereas those who lost weight and kept it off after
menopause were at lower risk than those who were weight stable
[64]. While several studies have reported an association between
adult weight gain and breast cancer risk [65], the identiﬁcation of
weight gain after menopause as an independent risk factor for
breast cancer risk highlights the importance of menopause as a
potential therapeutic window that could be targeted for disease
prevention. Further, the relationship between obesity and
menopause-related lobular involution remains an important but
relatively unexplored area of investigation.Preclinical modeling of postmenopausal breast
cancer
Menopause is a difﬁcult time period to study in women due to the
inability to readily identify its onset combined with wide inter-
individual variation in the length of time (2–5 years) in which this
process occurs. The use of pre-clinical models, however, has
allowed researchers to study the impact of loss of ovarian
function on breast cancer. The most commonly used model of
menopause is surgical ovariectomy (OVX). Similar to humans,
obesity has little effect on mammary tumor incidence in rodents
prior to OVX [66]. In contrast, after OVX, obese rats have fewer
tumors that regress, more tumors that progress and more new
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breast cancer risk and outcomes observed after menopause in
humans. Like menopause in women, OVX in rodents also pro-
motes a brief period of rapid weight gain and an associated
increase in adiposity [66]. It is during the early post-OVX period of
overfeeding that obesity-associated differences in tumor growth
emerge [67]. It has been shown that the inability to efﬁciently
store excess calories during this early post-OVX period is asso-
ciated with increased tumor multiplicity and burden [66]. In lean
animals, excess calories are taken up by peripheral tissues
(skeletal muscle, liver, adipose, and non-tumor-bearing mammary
glands) but not by mammary tumors. This likely occurs because
lean animals are metabolically ‘healthy’ when they enter OVX and
have the capacity to metabolize and store the inﬂux of calories
associated with OVX. Conversely, obese rodents display many
aspects of metabolic disease, and thus are less efﬁcient at storing
excess calories in their peripheral tissues. Importantly, after OVX,
their tumors show increased nutrient uptake, and this correlated
with increased markers of proliferation. Further, tumors that
develop in the obese environment have increased expression of
genes regulating glucose and fatty acid metabolism compared to
those that develop in lean rats [67].
Given that an impaired metabolic response to OVX-induced
weight gain appears critical to the emergence of obesity-
associated tumor promotion, the window of menopausal weight
gain may provide a narrowed window during which interventions
that improve metabolic control could be used to target mammary
tumor growth. Metformin, a commonly prescribed anti-diabetic
drug, is known to improve metabolic control. When administered
to obese tumor-bearing rats during the period of OVX-induced
weight gain, metformin signiﬁcantly decreased tumor burden
after 4 weeks [67]. Importantly, metformin's anti-cancer activity is
likely mediated, in part, through modiﬁcation of the tumor
microenvironment, as metformin treatment improves glucose
control, and decreases circulating glucose, lipids, and pro-
inﬂammatory cytokines available to the developing tumor. Several
population based studies support metformin's potential in
improving breast cancer outcomes in women [68] and better
breast cancer prognosis has been reported in diabetics who
received metformin prior to breast cancer diagnosis when com-
pared to other diabetic therapies and non-diabetic controls [69].
However, the results of prospective clinical trials on the use of
metformin in breast cancer patients have been unclear [70,71].
These data from rodent models would suggest that the timing of
metformin is critical and that this agent may be particularly
effective when administered during the peri- and early post-
menopausal windows, when weight gain and changes in meta-
bolism that contribute to tumor growth occur.Summary
Development of the mammary gland occurs in discrete and
identiﬁable lifecycle windows that coincide with ‘hot-spots’ for
breast cancer risk. These developmental windows are character-
ized by stromal–epithelial interactions that likely drive cancer
progression. Postpartum breast involution and peri-menopause
represent two lifecycle windows that are highly amenable to
intervention. While additional studies are certainly necessary to
conﬁrm these approaches, current data suggest that targetingthese ‘tissue-remodeling’ windows could provide the opportunity
to increase treatment efﬁcacy while decreasing the negative side
effects associated with long term treatments, thereby improving
effectiveness and patient acceptance of breast cancer prevention
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